Zenas BioPharma (NASDAQ:ZBIO) Director Buys $390,145.00 in Stock

Zenas BioPharma, Inc. (NASDAQ:ZBIO) Director Patricia Allen bought 15,700 shares of the company’s stock in a transaction that occurred on Thursday, February 12th. The shares were bought at an average price of $24.85 per share, with a total value of $390,145.00. Following the completion of the acquisition, the director directly owned 15,700 shares in the company, valued at $390,145. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Zenas BioPharma Trading Up 1.1%

Zenas BioPharma stock traded up $0.29 during trading hours on Friday, reaching $26.40. The company had a trading volume of 1,084,522 shares, compared to its average volume of 1,195,034. The company has a debt-to-equity ratio of 0.37, a current ratio of 5.66 and a quick ratio of 5.66. Zenas BioPharma, Inc. has a 12-month low of $6.11 and a 12-month high of $44.60. The company has a 50-day moving average price of $27.82 and a 200 day moving average price of $25.51. The firm has a market cap of $1.42 billion, a price-to-earnings ratio of -3.73 and a beta of -1.50.

Zenas BioPharma (NASDAQ:ZBIO) last released its quarterly earnings data on Wednesday, November 12th. The company reported ($1.22) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.87) by ($0.35).

Institutional Investors Weigh In On Zenas BioPharma

A number of large investors have recently modified their holdings of ZBIO. SR One Capital Management LP increased its position in shares of Zenas BioPharma by 2.6% during the fourth quarter. SR One Capital Management LP now owns 5,037,854 shares of the company’s stock valued at $182,924,000 after buying an additional 126,315 shares during the period. Federated Hermes Inc. boosted its position in Zenas BioPharma by 45.9% during the 4th quarter. Federated Hermes Inc. now owns 2,715,578 shares of the company’s stock valued at $98,603,000 after acquiring an additional 853,740 shares in the last quarter. Vanguard Group Inc. grew its holdings in shares of Zenas BioPharma by 25.0% during the 4th quarter. Vanguard Group Inc. now owns 1,453,065 shares of the company’s stock worth $52,761,000 after acquiring an additional 290,307 shares during the period. Geode Capital Management LLC raised its position in shares of Zenas BioPharma by 25.2% in the 4th quarter. Geode Capital Management LLC now owns 588,393 shares of the company’s stock worth $21,371,000 after acquiring an additional 118,358 shares in the last quarter. Finally, State Street Corp lifted its stake in shares of Zenas BioPharma by 16.1% in the 4th quarter. State Street Corp now owns 438,294 shares of the company’s stock valued at $15,914,000 after purchasing an additional 60,809 shares during the period.

Analysts Set New Price Targets

ZBIO has been the topic of a number of recent analyst reports. Citigroup raised their price target on shares of Zenas BioPharma from $27.00 to $46.00 and gave the stock a “buy” rating in a report on Tuesday, October 28th. HC Wainwright reiterated a “buy” rating and set a $44.00 target price on shares of Zenas BioPharma in a report on Tuesday. Weiss Ratings reissued a “sell (d-)” rating on shares of Zenas BioPharma in a research note on Monday, December 29th. Jefferies Financial Group reaffirmed a “buy” rating and set a $48.00 price target on shares of Zenas BioPharma in a research report on Tuesday, January 6th. Finally, Evercore initiated coverage on Zenas BioPharma in a report on Wednesday, November 26th. They issued an “outperform” rating and a $55.00 price objective for the company. Six equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $43.14.

Zenas BioPharma Company Profile

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.